0       0

HFSA's 20th Annual Scientific Meeting


Neprilysin Inhibitors: Clinically Available, Now What?


Description

  • What Have we Learned in the Two Years Since PARADIGM-HF? John McMurray, Glasgow, UK
  • Safety Concerns of ARNI’s: Real in the Real World? Akshay Desai, Boston, MA
  • ANRI’s for HFpEF, Hypertension, and CKD: Scott Solomon, Boston, MA
  • DEBATE: PRO - Every Ambulatory Patient Tolerating Moderate-dose ACEI/ARB Should Be Switched from ACEi/ARB to ARNIs; Milton Packer, Dallas, TX
  • DEBATE: CON- Every Ambulatory Patient Tolerating Moderate-dose ACEI/ARB Should Be Switched from ACEi/ARB to ARNIs: Nancy Sweitzer, Tucson, AZ
  • Panel Discussion

Moderator(s):

Speaker(s):

You must be logged in and own this session in order to post comments.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content